Human Tobacco Smokers in Early Abstinence Have Higher Levels of β2* Nicotinic Acetylcholine Receptors than Nonsmokers
Open accessAbstract
Nicotine, the addictive chemical in tobacco smoke, initiates its actions in brain through nicotinic acetylcholine receptors (nAChRs). In particular, nAChRs containing β 2-subunits (β 2*-nAChRs) the most prevalent subtype, mediate the reinforcing properties of nicotine. We hypothesized that abnormal numbers of β 2*-nAChRs during early abstinence contribute to the perpetuation of addiction to tobacco smoking. Using molecular imaging, specifically single-photon emission computed tomography with the nAChR agonist radiotracer [123 I]5-IA-85380 ([123 I]5-IA), we imaged β 2*-nAChR availability in human smokers. First, using nonhuman primates treated chronically with nicotine, we estimated the time interval necessary for smokers to abstain from smoking so that residual nicotine would not interfere with [123 I]5-IA binding to the β 2*-nAChR as ∼7 d. Thus, we imaged human smokers at 6.8 ± 1.9 d (mean ± SD) of abstinence. Abstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels. In smokers, [123 I]5-IA uptake was significantly higher throughout the cerebral cortex (26–36%) and in the striatum (27%) than in nonsmokers, suggesting higher β 2*-nAChR in recently abstinent smokers. β 2*-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke. Higher brain β 2*-nAChR during early abstinence indicates that, when smokers quit smoking, they do so in the face of a significant increase in the receptors normally activated by nicotine. Greater β 2*-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence.
AI snapshot
Written from the paper’s full text.
TL;DR
Using [123I]5-IA SPECT, this study found that human smokers in early abstinence have higher brain β2*-nicotinic acetylcholine receptor availability than nonsmokers. The authors suggest this upregulation may influence the ability to maintain smoking abstinence.
Key findings
- Smokers imaged after 6.8 ± 1.9 d of abstinence showed significantly higher [123I]5-IA uptake than nonsmokers throughout cerebral cortex (26–36%) and in striatum (27%); region-of-interest analyses also showed higher uptake in cerebellum (25.2%) but not thalamus (8.7%, p = 0.1651).
- In nonhuman primates, [123I]5-IA binding decreased 41–65% after 1–2 d of nicotine withdrawal, then increased 240–276% after 7 d of withdrawal, supporting an approximately 7 d abstinence interval before human imaging.
- In smokers, β2*-nAChR availability correlated with days since last cigarette and with urge to smoke to relieve withdrawal symptoms, but not with severity of nicotine dependence, severity of nicotine withdrawal, or desire to smoke.
Methods
- Two male adolescent rhesus macaques received oral nicotine dose escalation and were imaged with [123I]5-IA SPECT at baseline, after 6 weeks of nicotine plus 1–2 d withdrawal, and after 8 weeks of nicotine plus 7 d withdrawal.
- Human smokers (n = 16) and nonsmokers (n = 16) matched on age and sex were imaged with [123I]5-IA SPECT using a bolus-plus-constant-infusion paradigm; smokers abstained for 6.8 ± 1.9 d, confirmed by urinary cotinine and expired carbon monoxide.
- Regional β2*-nAChR availability was measured as V_T′ using MRI-guided regions of interest and voxel-based SPM2 analyses; group differences used MANOVA and t tests, and clinical correlations used Pearson’s correlation.
Limitations
- The paper states that a species difference cannot be ruled out because nonhuman primates were male adolescents while human smokers were male and female adults, and it notes that interindividual variability in nicotine metabolism/CYP2A6 is expected.
- The paper reports that technical problems precluded determining plasma levels in one monkey at 6 weeks/2 d withdrawal.
- Evident from the text: human samples were small (n = 16 per group), cross-sectional, and correlational; V_T′ interpretation assumes no change in affinity and no difference in nondisplaceable uptake.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
5 of 36 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured
- Premisecitation
Nicotine competes with [123I]5-IA binding for binding to nAChRs.
“Because nicotine competes with [ 123 I]5-IA binding for binding to nAChRs (Mukhin et al., 2000)”
Quote in the paperSubstantial claim1 of 1 sources checked- cites Mukhin et al., 2000 source
The available indexed passages (no section or page labels) list nicotine and 5-iodo-A-85380 as receptor ligands, but do not describe nicotine competing with [123I]5-IA for binding. Searches for nicotine displacement, inhibition, and competitive binding returned no passage addressing that relationship. (LLM, conf=0.70)
Experimental — accuracy not yet measured
- Premisecitation
[123I]5-IA is a radioligand that has specificity for the agonist binding site on β2*-nAChRs.
“With the recent development of [ 123 I]5-IA-85380 ([ 123 I]5-IA), a radioligand that has specificity for the agonist binding site on  2 *- nAChRs (Musachio et al., 1998(Musachio et al., , 1999;;Horti et al., 1999)”
Quote in the paperSubstantial claim2 of 3 sources checked- cites Musachio et al., 1998 source
The Results (page not provided) show that nAChR agonists inhibited [125I]5-IA binding in mouse brain, and the Discussion reports specificity for central nAChRs. However, the Discussion only predicts selectivity for the α4β2 subtype; it does not establish specificity for the agonist binding site on β2*-nAChRs. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites Musachio et al., 1999 source
The Discussion (page not provided) describes [123I]5-IA as a highly specific probe for central nAChRs and reports that the agonist cytisine blocked its uptake in baboon brain. It does not establish specificity for the agonist binding site on β2*-nAChRs; it says only that radioiodinated 5-IA might be more selective for the α4β2 subtype. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites Horti et al., 1999 source
- Premisecitation
Greater β2*-nAChR availability appears attributable to occupancy of the nicotine binding site that bridges the α/β subunit interface in an immature, low-affinity conformation that facilitates glycosylation and maturation of the α4β2 nAChR to a more stable conformation with higher affinity for nicotine.
“but instead appears to be attributable to occupancy of the nicotine binding site that bridges the ␣/ subunit interface of the nAChR in an immature, low-affinity conformation that facilitates glycosylation and maturation of the ␣ 4  2 nAChR to a more stable conformation with higher affinity for nicotine (Darsow et al., 2005;Sallette et al., 2005).”
Quote in the paperSubstantial claim1 of 2 sources checked - Findingown data
β2*-nAChR availability in recently abstinent smokers correlated with the urge to smoke to relieve withdrawal symptoms.
“ 2 *-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke.”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
In recently abstinent smokers, [123I]5-IA uptake was significantly higher throughout the cerebral cortex (26-36%) and in the striatum (27%) than in nonsmokers.
“In smokers, [ 123 I]5-IA uptake was significantly higher throughout the cerebral cortex (26 -36%) and in the striatum (27%) than in nonsmokers, suggesting higher  2 *-nAChR in recently abstinent smokers.”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
In nonhuman primates, clearance of nicotine or a pharmacologically active metabolite takes several days after the last administration to clear brain.
“also provided the first evidence that clearance of nicotine or a pharmacologically active metabolite (a metabolite that is occupying the receptor and blocking the radioligand from binding) takes several days after the last administration to clear brain.”
Quote in the paperSubstantial claim- Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
- Findingown data
Voxel-based analyses demonstrated significantly higher β2*-nAChR availability for a large cluster including parietal cortex, cingulate gyrus, middle temporal gyrus, and two smaller clusters in middle frontal gyrus in recently abstinent smokers compared with nonsmokers.
“Voxel-based analyses (df ϭ 30) demonstrated significantly higher  2 *-nAChR availability for a large cluster (T ϭ 5.20; p ϭ 0.000 corrected) that included the parietal cortex [Brodmann's area 40 (BA 40)], cingulate gyrus (BA 31), middle temporal gyrus (BA 39), and for two smaller clusters in the middle frontal gyrus that included BA 6 (T ϭ 4.43; p ϭ 0.03 corrected) and BA 9 (T ϭ 4.19; p ϭ 0.04”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
β2*-nAChR availability in recently abstinent smokers did not correlate with the severity of nicotine withdrawal.
“ 2 *-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke.”
Quote in the paperNot a substantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
In nonhuman primates, average regional [123I]5-IA binding decreased from baseline (41-65% change) after 1-2 days of nicotine withdrawal.
“Average regional [ 123 I]5-IA binding decreased from baseline (41-65% change) after 1-2 d withdrawal”
Quote in the paperSubstantial claim- The authors state this as an assumption: V_T' is proportional to binding potential (Bmax/KD), assuming no change in affinity (KD) and that nondisplaceable uptake does not differ between animals and studies.
- Findingown data
In smokers, β2*-nAChR availability in the anterior cingulate cortex and frontal cortex (BA 5 and BA 6) correlated positively with the number of days since last cigarette.
“The voxel-based analyses demonstrated that  2 *-nAChR availability in the ante- rior cingulate cortex and frontal cortex (BA 5 and BA 6) correlated significantly with the number of days since last cigarette, suggesting that  2 *-nAChR availability increased progressively with continued days of abstinence.”
- Also stated in: § Discussion · plain
“Days since last cigarette Anterior cingulate 14,12,24 405 8.62 0.95 0.004 0.020”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Also stated in: § Discussion · plain
- Findingown data
In smokers, β2*-nAChR availability in the postcentral gyrus/somatosensory cortex (BA 43) correlated negatively with the urge to smoke to relieve withdrawal symptoms.
“We also observed a significant negative correlation between  2 *-nAChR availability in the post- central gyrus or somatosensory cortex (BA 43) and the urge to smoke to relieve withdrawal symptoms (Table 3).”
- Also stated in: § Discussion · plain
“we did observe a significant relationship between  2 -nAChR availability in the sensorimotor cortex (Brodmann's area 43) and the urge to smoke to relieve withdrawal symptoms.”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Also stated in: § Discussion · plain
- Findingown data
Plasma cotinine levels in the nonhuman primates were within the range of plasma cotinine levels in human tobacco smokers.
“Plasma cotinine levels in the nonhuman primates were within the range of plasma cotinine levels in human tobacco smokers (Ͼ15 ng/ml, 1 pack per day; Ͼ300 ng/ml, Ͼ25 cigarettes per day).”
Quote in the paperNot a substantial claim - Findingown data
β2*-nAChR availability in recently abstinent smokers correlated with days since last cigarette.
“ 2 *-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke.”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
β2*-nAChR availability in recently abstinent smokers did not correlate with the desire to smoke.
“ 2 *-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke.”
Quote in the paperNot a substantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
β2*-nAChR availability in recently abstinent smokers did not correlate with the severity of nicotine dependence.
“ 2 *-nAChR availability in recently abstinent smokers correlated with the days since last cigarette and the urge to smoke to relieve withdrawal symptoms but not the severity of nicotine dependence, severity of nicotine withdrawal, or the desire to smoke.”
Quote in the paperNot a substantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Findingown data
In nonhuman primates, higher β2*-nAChR availability is attributable to nicotine rather than other chemicals in tobacco smoke.
“These findings were substantiated by our experiment in nonhuman primates that confirmed that higher  2 *-nAChR availability is at- tributable to nicotine (vs other chemicals in tobacco smoke)”
Quote in the paperSubstantial claim- Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
- Findingown data
There was no relationship between the desire to smoke a cigarette to enhance positive affect and β2*-nAChR availability.
“We observed no relationship between the desire to smoke a cigarette to enhance positive affect and  2 *-nAChR availability.”
Quote in the paperNot a substantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Interpretationown data
If there are fewer β2*-nAChRs in the sensorimotor cortex, there is a greater urge to smoke to relieve withdrawal symptoms.
“Thus, if there are fewer  2 -nAChRs in the sensorimotor cortex, there is a greater urge to smoke to relieve withdrawal symptoms.”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Study design and conductown data
Smoking status was confirmed by plasma cotinine levels and carbon monoxide levels in expired air.
“Smoking status was confirmed by plasma cotinine levels (215.4Ϯ 140.4 ng/ml) and also by carbon monoxide levels in expired air (18.4 Ϯ 9.8 ppm at intake).”
Quote in the paperSubstantial claim- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Interpretationreasoning
The positive correlation between β2*-nAChR availability and days since last cigarette suggests that nicotine has not yet completely cleared from the binding site.
“suggesting that nicotine has not yet completely cleared from the binding site.”
Quote in the paperSubstantial claim- Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
- Interpretationreasoning
Higher brain [123I]5-IA uptake in recently abstinent smokers indicates greater availability of nicotine binding sites on β2*-nAChRs.
“Higher brain [ 123 I]5-IA uptake in recently abstinent smokers suggests greater availability of nicotine binding sites on  2 *- nAChRs.”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Interpretationcitation
Greater β2*-nAChR availability in tobacco smokers likely represents greater numbers of desensitized and inactivated nAChRs.
“Functionally, greater  2 *-nAChR availability in tobacco smokers likely represents greater numbers of desensitized and inactivated nAChRs (Wonnacott, 1990;Dani and Heinemann, 1996).”
Quote in the paperNot a substantial claim0 of 2 sources checked- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Interpretationown data
Adaptive changes in β2*-nAChR availability are not responsible for the overall severity of nicotine withdrawal symptoms measured after 4-9 days of abstinence.
“The lack of a relationship with the MWS score suggests that adaptive changes in  2 -nAChR availability are not responsible for the overall severity of nicotine withdrawal symptoms measured after 4 -9 d of abstinence”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Premisecitation
nAChRs containing β2-subunits (β2*-nAChRs) mediate the reinforcing properties of nicotine.
“In particular, nAChRs containing  2 -subunits ( 2 *-nAChRs) the most prevalent subtype, mediate the reinforcing properties of nicotine.”
- Also stated in: § Introduction · plain
“Because the reinforcing properties of nicotine have been linked specifically to nAChRs that contain the  2 subunit ( 2 *-nAChRs) (Picciotto et al., 1998)”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Picciotto et al., 1998 source
- Also stated in: § Introduction · plain
- Interpretationown data
β2*-nAChRs in the somatosensory cortex contribute to the urge to smoke to relieve withdrawal.
“and that  2 *-nAChRs in the somatosensory cortex contribute to the urge to smoke to relieve withdrawal.”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Study design and conductown data
Equilibrium was established by hour 4 after injection of the radiotracer, as demonstrated by stable levels of regional [123I]5-IA uptake.
“Equilibrium was established by hour 4 after injection of the radiotracer, as demonstrated by stable levels of regional [ 123 I]5-IA uptake with average changes of 0.43%/h for cortical regions and 0.62%/h for subcortical areas.”
Quote in the paperSubstantial claim- The authors state this as an assumption: V_T' is proportional to binding potential (Bmax/KD), assuming no change in affinity (KD) and that nondisplaceable uptake does not differ between animals and studies.
- Study design and conductown data
Urine cotinine concentrations declined from day 1 to day 4 of abstinence.
“Urine cotinine concentrations declined from day 1 (range of 1000 -10,000 ng/ml cotinine) for all smokers, except one (100 -250 ng/ml) to day 4 of abstinence (0 -1000 ng/ml).”
Quote in the paperSubstantial claim- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Interpretationown data
Higher brain β2*-nAChR during early abstinence indicates that when smokers quit smoking, they do so in the face of a significant increase in the receptors normally activated by nicotine.
“Higher brain  2 *-nAChR during early abstinence indicates that, when smokers quit smoking, they do so in the face of a significant increase in the receptors normally activated by nicotine.”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Interpretationreasoning
Occupancy of β2*-nAChR by nicotine in the sensorimotor cortex may contribute to sensory cues or 'tasting of cigarettes' that play a role in relief of craving and the urge to smoke.
“Given that the sensorimotor cortex is involved in mouth and taste reception, these findings may suggest that occupancy of  2 -nAChR by nicotine in the sensorimotor cortex may contribute to some of the sensory cues or”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Rose and Behm, 1994 source
- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Interpretationown data
Approximately 7 days of abstinence from smoking is needed before imaging to ensure that residual nicotine and/or its metabolites do not interfere with [123I]5-IA binding to β2*-nAChR in smokers.
“First, using nonhuman primates treated chronically with nicotine, we estimated the time interval necessary for smokers to abstain from smoking so that residual nicotine would not interfere with [ 123 I]5-IA binding to the  2 *-nAChR as ϳ7 d.”
- Also stated in: § Results · hedged
“suggesting that ϳ7 d of abstinence from smoking is needed before imaging to ensure that residual nicotine and/or its metabolite(s) did not interfere with [ 123 I]5-IA binding to  2 *-nAChR in smokers.”
Quote in the paperSubstantial claim- Rests on an assumption: The time course of nicotine clearance and receptor availability in nonhuman primates is similar enough to humans to determine the necessary abstinence interval for human smokers.
- Also stated in: § Results · hedged
- Interpretationcitation
Decreased β2*-nAChR availability and elevated plasma and urinary cotinine at 1-2 days of withdrawal suggest that residual nicotine or a metabolite blocked [123I]5-IA from binding to β2*-nAChR during the first 48 hours of nicotine withdrawal.
“Decreased  2 *-nAChR avail- ability and elevated plasma and urinary cotinine at 1-2 d withdrawal, interpreted in combination with the in vitro data (for review, see Esterlis et al., 2005) demonstrating greater concentrations of nAChRs within hours of the last nicotine exposure, suggest that residual nicotine or a metabolite, such as cotinine or nornicotine, blocked [ 123 I]5-IA from binding to ”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Esterlis et al., 2005
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- The authors state this as an assumption: V_T' is proportional to binding potential (Bmax/KD), assuming no change in affinity (KD) and that nondisplaceable uptake does not differ between animals and studies.
- Interpretationreasoning
Greater β2*-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence.
“Greater  2 *-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence.”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
- Interpretationreasoning
Nicotine and/or its metabolites may accumulate in nonspecific compartments in brain, such as white matter, and then diffuse slowly into gray matter areas with higher levels of nAChRs.
“Therefore, nicotine and/or its metabolites may accumulate in nonspecific compartments in brain, such as white matter, and then diffuse slowly into the gray matter areas in which there are higher levels of nAChRs.”
Quote in the paperSubstantial claim - Interpretationreasoning
β2*-nAChR availability during early abstinence likely plays an important role in the ability of smokers to stay abstinent.
“ 2 *-nAChR availability during early abstinence likely plays an important role in the ability of smokers to stay abstinent.”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- May combine two claims. 14
- Classified as probably not a substantial claim. 13
May combine two claims.
PremisecitationGreater β2*-nAChR availability is not associated with changes in β2*-nAChR mRNA, protein synthesis, rate of receptor internalization, postendocytic trafficking, or lysosomal degradation.
“Greater  2 *- nAChR availability is not associated with changes in  2 *-nAChR mRNA (Marks et al., 1992;Peng et al., 1994;Zhang et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al., 2005)”
Quote in the paperSubstantial claim1 of 3 sources checkedMay combine two claims.
Findingown dataThe concentration of unmetabolized [123I]5-IA and the percentage of [123I]5-IA not bound to plasma proteins did not vary significantly between nonsmokers and smokers.
“The concentration of unmetabolized [ 123 I]5-IA and the percentage of [ 123 I]5-IA not bound to plasma proteins ( f 1 ) did not vary significantly between nonsmokers and smokers [0.31 Ϯ 0.09 and 0.26 Ϯ 0.08 kBq/ml, respectively; 95% confidence interval (Ϫ0.114, 0.009); p ϭ 0.09; and 35.4 Ϯ 3.2 and 36.6 Ϯ 4.9%, respectively; p ϭ 0.44].”
Quote in the paperSubstantial claim- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
May combine two claims.
Findingown dataThere were no significant correlations between regional β2*-nAChR availability and number of cigarettes smoked per day, severity of nicotine dependence, severity of nicotine withdrawal, or the urge to smoke (general) in either region-of-interest or voxel-based analyses.
“There were no significant correlations between regional  2 *-nAChR availability and number of cigarettes smoked per day, severity of nicotine dependence, severity of nicotine withdrawal, or the urge to smoke for either region of interest analyses or voxel-based analyses.”
- Also stated in: § Discussion · plain
“We did not observe a relationship between  2 *-nAChR avail- ability in brain and the number of cigarettes smoked per day”
- Also stated in: § Discussion · plain
“there was no evidence for a significant correlation between  2 *-nAChR avail- ability and the severity of nicotine withdrawal assessed by the MWS on the scan day.”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Also stated in: § Discussion · plain
May combine two claims.
Findingown dataβ2*-nAChR availability (VT') is higher in recently abstinent smokers than nonsmokers in the striatum, cerebellum, and cerebral cortex (parietal, frontal, anterior cingulate, temporal, and occipital cortices), but not in the thalamus.
“This report provides the first direct evidence that brain  2 *-nAChR densities are higher in the striatum, cerebellum, and cerebral cortex during early abstinence in living human smokers compared with nonsmokers”
- Also stated in: § Discussion · plain
“striatal, cortical, and cerebellar [ 123 I]5-IA uptake values were significantly higher in the smokers compared with the nonsmokers ( p values ϭ 0.0002, 0.0001, and 0.0013, respectively), whereas there was no significant difference in thalamic [ 123 I]5-IA uptake.”
- Also stated in: § Discussion · plain
“recently abstinent smokers have more cortical, striatal, and cerebellar  2 *-nAChR sites available for binding than nonsmok- ers”
Quote in the paperSubstantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
- Also stated in: § Discussion · plain
May combine two claims.
Findingown dataIn smokers, β2*-nAChR availability was higher throughout the cerebral cortex, striatum, and cerebellum but not thalamus, whereas nicotine-treated nonhuman primates exhibited higher [123I]5-IA binding throughout all brain regions.
“There were notable regional differences in  2 *-nAChR avail- ability in smokers with robustly higher levels throughout the cerebral cortex, striatum, and cerebellum but not thalamus compared with the nicotine-treated nonhuman primates, which exhibited higher [ 123 I]5-IA binding throughout all brain regions.”
Quote in the paperSubstantial claim- Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
May combine two claims.
Findingown dataIn nonhuman primates, after 6 weeks of oral nicotine, 1-2 days of withdrawal caused a 41-65% decrease in [123I]5-IA uptake, and after 8 weeks, 7 days of withdrawal caused a >200% increase.
“Note the reproducibility of measurement indicated by lack of change between B1 and B2, the profound decrease followed by 1-2 d of withdrawal (41-65% change at 6 weeks of nicotine treatment), and the dramatic increase followed by 7 d of withdrawal (Ͼ200% after 8 weeks of nicotine treatment).”
Quote in the paperNot a substantial claim- Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
Probably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenSelf-reports of menstrual cycle phase were validated by plasma estrogen and progesterone levels.
“Self-reports of menstrual cycle phase were validated by plasma estrogen and progesterone levels.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductcitationRegional β2*-nAChR availability was determined by V_T' (regional activity/total plasma parent), a highly reproducible outcome measure.
“Regional  2 *-nAChR availability was determined by V T Ј (regional activity/total plasma parent), a highly reproducible outcome measure (Staley et al., 2005).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites Staley et al., 2005
- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
Probably not a substantial claim: may not pass S3 (load-bearing).
InterpretationreasoningThe ability of nicotine to regulate β2*-nAChR availability may be age or sex dependent, because the nonhuman primates were male adolescents and the smokers were male and female adults.
“Although a species difference cannot be ruled out, this divergence may suggest that the ability of nicotine to regulate  2 *-nAChR availability is age or sex dependent because the nonhuman primates were male adolescents and the smokers were male and female adults (Slotkin, 2002;Nguyen et al., 2003).”
Quote in the paperNot a substantial claim0 of 2 sources checked- Rests on an assumption: The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
Classified as probably not a substantial claim.
PremisecitationAnimals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain.
“animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et al., 1983(Marks et al., , 1985(Marks et al., , 1992;;Schwartz and Kellar, 1983)”
Quote in the paperSubstantial claim0 of 3 sources checkedProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductcitationInter-rater reliability for V_T' across eight brain regions ranged between 0.82 and 0.97.
“The interclass coefficient to assess inter-rater reliability (Rousson et al., 2002) ranged between 0.82 and 0.97 for the V T Ј measure across the eight brain regions.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Rousson et al., 2002 source
- Rests on an assumption: V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
Classified as probably not a substantial claim.
Study design and conductnone givenAbstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels.
“Abstinence was confirmed by daily assessments of urinary cotinine and expired carbon monoxide levels.”
Quote in the paperSubstantial claim- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
Classified as probably not a substantial claim.
PremisecitationPostmortem studies of human brain have suggested that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers.
“Postmortem studies of human brain have suggested that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988;Breese et al., 1997;Perry et al., 1999)”
Quote in the paperSubstantial claim0 of 3 sources checkedMay combine two claims.
Study design and conductown dataOn the SPECT scan day, urinary cotinine levels were <250 ng/ml for 14 of 16 smokers and <1000 ng/ml for two smokers.
“On the SPECT scan day, urinary cotinine levels were Ͻ250 ng/ml for 14 of 16 smokers and Ͻ1000 ng/ml for two smokers.”
Quote in the paperSubstantial claim- Rests on an assumption: Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
Probably not a substantial claim: may not pass S3 (load-bearing).
InterpretationcitationThe relationship between greater β2*-nAChR availability and nAChR function may vary in a region-dependent manner attributable to different subunit combinations that demonstrate increased agonist binding but differ in effects on function.
“The relationship between greater  2 *-nAChR availability and nAChR function may vary in a region-dependent manner attributable to different subunit combinations that demonstrate increased agonist binding but differ in the effects on function (Rush et al., 2002).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Rush et al., 2002 source
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
PremisecitationCraving (the urge to smoke) is a prominent feature of nicotine dependence and is a primary factor associated with relapse.
“Although most withdrawal symptoms resolve after a few days of abstinence, craving (i.e., the urge to smoke) is a prominent feature of nicotine dependence (Tiffany and Drobes, 1991) and is a primary factor associated with relapse (Killen et al., 1997).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites Tiffany and Drobes, 1991 source
- cites Killen et al., 1997
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
InterpretationcitationThe rapid pharmacokinetics of nicotine were observed after a single administration of a trace dose of intravenous nicotine, and accumulation of nicotine and/or metabolites in brain may differ with protracted and repeated nicotine administration.
“The rapid pharmacokinetics were observed, however, after a single administration of a trace dose of intravenous nicotine, and the accumulation of nicotine and/or metabolites (Vainio and Tuominen, 2001) in brain may differ with protracted and repeated nicotine administration.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Vainio and Tuominen, 2001 source
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.
Premisenone givenUrinary cotinine, the primary metabolite of nicotine, has a longer half-life than nicotine and appears to be a useful indicator of the clearance of nicotine or a metabolite from brain.
“Urinary cotinine, the primary metabolite of nicotine, has a longer half-life than nicotine and appears to be a useful indicator of the clearance of nicotine or a metabolite from brain.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing).
InterpretationreasoningThe severity of nicotine withdrawal is likely determined by the complex interplay between β2*-nAChRs and other neurochemical systems.
“Because of the myriad of symptoms and the wide-ranging actions of nicotine on brain neurochemistry, the severity of nicotine withdrawal is likely determined by the complex interplay between  2 *-nAChRs and other neurochemi- cal systems.”
Quote in the paperNot a substantial claim- Rests on an assumption: The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
May combine two claims.
PremisecitationNicotine is highly lipophilic and, when radiolabeled, demonstrates very high levels of nonspecific brain uptake.
“Nicotine is highly lipophilic and, when radiolabeled, demonstrates very high levels of nonspecific brain uptake (Broussolle et al., 1989;Muzic et al., 1998).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites Broussolle et al., 1989 source
- cites Muzic et al., 1998
Probably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationInterindividual variability in nicotine metabolism in human smokers is expected because individuals with different CYP2A6 genotypes differentially metabolize nicotine.
“Interindividual variability in nicotine metabolism in human smokers is expected because individuals with different CYP2A6 genotypes differentially metabolize nicotine (Tyndale and Sellers, 2001).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites Tyndale and Sellers, 2001
May combine two claims.
PremisecitationThe α4β2 combination is the most prevalent β2*-nAChR combination and the most sensitive to upregulation by nicotine.
“Although  2 subunits exist in several different combi- nations with ␣ 2 , ␣ 3 , ␣ 4 , and ␣ 6 subunits, the ␣ 4  2 combination is most prevalent and also the most sensitive to upregulation by nicotine (Nguyen et al., 2003;Sallette et al., 2004).”
Quote in the paperSubstantial claim0 of 2 sources checkedMay combine two claims.
Premisenone givenLarge individual differences in urinary cotinine clearance have been observed in human smokers over the first week of abstinence, with cotinine levels declining to levels comparable with those in nonsmokers over a 4-7 day period after smoking cessation.
“Importantly, large individual differences in urinary cotinine clearance have been observed in human smokers over the first week of abstinence, with cotinine levels declining to levels comparable with those in nonsmokers over a 4 -7 d period after smoking cessation.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe terminal half-life of nicotine is 1.6 h in macaques, and radiolabeled nicotine rapidly clears from brain.
“The apparent long residence time of nicotine on  2 *-nAChR in brain is sur- prising given that the terminal half-life of nicotine is 1.6 h in macaques (Schoedel et al., 2003) and that radiolabeled nicotine rapidly clears from brain (Crooks and Dwoskin, 1997;Crooks et al., 1997).”
Quote in the paperSubstantial claim0 of 3 sources checked- cites Schoedel et al., 2003 source
- cites Crooks and Dwoskin, 1997
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites Crooks et al., 1997
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
The paper relies on this without support.
Nicotine initiates its actions in the brain through nicotinic acetylcholine receptors (nAChRs).
“Nicotine, the addictive chemical in tobacco smoke, initiates its actions in brain through nicotinic acetylcholine receptors (nAChRs).”
The paper relies on this without support.
The addictive properties of tobacco smoke are attributed primarily to nicotine.
“Although tobacco smoke contains Ͼ4000 chemicals, its addictive properties have been attributed primarily to nicotine.”
The authors state this as an assumption.
V_T' is proportional to binding potential (Bmax/KD), assuming no change in affinity (KD) and that nondisplaceable uptake does not differ between animals and studies.
“The primary outcome measure for regional brain uptake was V T Ј, which is proportional to the binding potential (BP) (B max /K D ), assuming that there is no change in affinity (K D ) and that nondisplaceable uptake does not differ between animals and studies.”
The paper relies on this without support.
The time course of nicotine clearance and receptor availability in nonhuman primates is similar enough to humans to determine the necessary abstinence interval for human smokers.
“First, using nonhuman primates treated chronically with nicotine, we estimated the time interval necessary for smokers to abstain from smoking so that residual nicotine would not interfere with [ 123 I]5-IA binding to the  2 *-nAChR as ϳ7 d.”
The paper relies on this without support.
V_T' in humans reflects β2*-nAChR availability without changes in affinity or nondisplaceable uptake.
“Regional  2 *-nAChR availability was determined by V T Ј (regional activity/total plasma parent), a highly reproducible outcome measure (Staley et al., 2005).”
The paper relies on this without support.
Urinary cotinine levels below 250 ng/ml indicate sufficient abstinence from smoking.
“On the SPECT scan day, urinary cotinine levels were Ͻ250 ng/ml for 14 of 16 smokers and Ͻ1000 ng/ml for two smokers.”
The paper relies on this without support.
The nonhuman primate findings on nicotine-induced β2*-nAChR upregulation and clearance generalize to human smokers.
“These findings were substantiated by our experiment in nonhuman primates that confirmed that higher  2 *-nAChR availability is at- tributable to nicotine (vs other chemicals in tobacco smoke)”
The paper relies on this without support.
The [123I]5-IA VT' measure reflects β2*-nAChR availability (density of binding sites) in human brain without confounding by differences in blood flow or radioligand delivery.
“Higher brain [ 123 I]5-IA uptake in recently abstinent smokers suggests greater availability of nicotine binding sites on  2 *- nAChRs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Our data extend the findings of previous studies which showed that the upregulation of the β2*-nAChR in recently abstinent tobacco smokers was temporary and could be measured with [123I]5-IA SPECT imaging.
“In summary, our data extend the findings of previous studies8, 18 which showed that the upregulation of the β2*-nAChR in recently abstinent tobacco smokers was temporary and could be measured with [123I]5-IA SPECT imaging.”
From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]
The Results report higher β2*-nAChR availability in recently abstinent smokers than in nonsmokers, measured with [123I]5-IA SPECT. The study does not establish that this upregulation was temporary in human smokers; it imaged them during early abstinence rather than following receptor levels over time. (LLM, conf=0.88)
Experimental — accuracy not yet measuredChronic smokers have more cortical, striatal, and cerebellar β2* nAChRs than non-smokers.
“it was found that chronic smokers have more cortical, striatal, and cerebellar β2* nAChRs than non-smokers (Staley et al. 2006).”
From Nicotine Withdrawal (2015) · cites this paper as Staley et al. 2006
The Discussion reports higher β2*-nAChR densities in the cortex, striatum, and cerebellum of smokers than nonsmokers, and Table 2 shows higher availability in those regions. The smokers were studied during early abstinence; the claim omits that condition and therefore implies a broader finding about chronic smokers. (LLM, conf=0.84)
Experimental — accuracy not yet measuredβ2*-nAChR availability is higher in recently abstinent smokers compared to never smokers.
“β2*-nicotinic acetylcholine receptor (β2*-nAChR) availability is higher in recently abstinent smokers compared to never smokers.”
From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]
The difference between recently abstinent smokers and never smokers in the previous study was of greater magnitude (26-36% in cerebral cortex and 27% in striatum) than in the current study (21-29% in cerebral cortex and 22% in striatum).
“The difference between recently abstinent smokers and never smokers in the previous study8 was of a greater magnitude, e.g., 26-36% in the cerebral cortex and 27% in the striatum, than in the current study, e.g., 21-29% in the cerebral cortex and 22% in the striatum.”
From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]
A previous study found a negative correlation between the urge to smoke to relieve withdrawal symptoms and β2*-nAChR availability in the sensorimotor cortex at approximately 1 week of abstinence.
“We previously found a negative correlation between the urge to smoke to relieve withdrawal symptoms and β2*-nAChR availability in the sensorimotor cortex at approximately 1 week of abstinence8.”
From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]
Smokers at one week of abstinence have significantly higher β2*-nAChR availability in the cortex, striatum and cerebellum, but not thalamus, compared to nonsmokers.
“Consistent with our previous study8 we report significantly higher β2*-nAChR availability in smokers at one week of abstinence in the cortex, striatum and cerebellum, but not thalamus compared to nonsmokers.”
From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]
This study and previous in vivo PET and SPECT studies report no upregulation of thalamic β2*-nAChR availability during acute abstinence.
“This study and previous in vivo PET78 and SPECT8, 18 studies report no upregulation of thalamic β2*-nAChR availability during acute abstinence, which conflicts with postmortem2 and animal8, 79 studies.”
From β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking (2009) · cites this paper as [8]
The increased depressive symptoms following acute smoking cessation might be explained by clearance of nicotine coupled with persistent nAChR upregulation, resulting in increased ability of ACh to activate upregulated nAChRs.
“this hypothesis suggests that the increased depressive symptoms observed in some patients following acute cessation from smoking might be explained by the fact that the clearance of nicotine following smoking cessation coupled with persistent nAChR upregulation (Staley et al., 2006) results in increased ability of ACh to activate these upregulated nAChRs.”
From It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood (2008) · cites this paper as Staley et al., 2006
The increased nAChR pool from chronic nicotine might affect the ability to maintain abstinence in clinical populations.
“and might impact the ability to maintain abstinence in the clinical population (Staley et al. 2006).”
From Nicotine Withdrawal (2015) · cites this paper as Staley et al. 2006
β2* nAChR levels in anterior cingulate and frontal cortex are significantly correlated with number of days after smoking cessation.
“Furthermore, β2* nAChRs in the anterior cingulate and frontal cortex were significantly correlated with the number of days following cessation of smoking.”
From Nicotine Withdrawal (2015) · cites this paper as Staley et al. 2006
Upregulation of nAChR expression can persist for several days after termination of chronic nicotine.
“Additionally, studies have demonstrated that upregulation of nAChR expression can persist for several days following termination of chronic nicotine (Pietila et al. 1998; Staley et al. 2006).”
From Nicotine Withdrawal (2015) · cites this paper as Staley et al. 2006
β2* nAChR availability in post-central gyrus or somatosensory cortex is significantly negatively correlated with urge to relieve withdrawal symptoms by smoking.
“In addition, a significant negative correlation was observed between β2* nAChR availability in the post-central gyrus or somatosensory cortex and the urge to relieve withdrawal symptoms by smoking (Staley et al. 2006).”
From Nicotine Withdrawal (2015) · cites this paper as Staley et al. 2006
Increased nAChRs are seen with in vivo imaging in baboon brain after chronic nicotine and in the brains of current smokers.
“Increased nAChRs are also seen with in vivo imaging techniques in baboon brain after chronic administration of nicotine (Kassiou et al., 2001) and the brains of current smokers (Staley et al., 2006;Wu ¨llner et al., 2008).”
From Chronic Sazetidine-A at Behaviorally Active Doses Does Not Increase Nicotinic Cholinergic Receptors in Rodent Brain (2012) · cites this paper as Staley et al., 2006
In chronic smokers, nicotine abstinence increases the availability of unbound α4β2 nicotinic acetylcholine receptors, which contributes to abstinence symptoms.
“In chronic smokers, abstinence from nicotine increases the availability of unbound α4β2 nAChRs, which in turn contributes to abstinence symptoms (35).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [35]
Elevated nAChR levels in abstinent smokers correlate with urge to smoke.
“Abstinent smokers compared to nonsmokers had higher levels of β2* nAChRs, which returned to baseline between 3-12 weeks, and elevated nAChR levels correlated with urge to smoke (Cosgrove et al., 2009; Mamede et al., 2007; Staley et al., 2006).”
From The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation (2012) · cites this paper as Staley et al., 2006
Abstinent smokers have higher β2* nAChR levels than nonsmokers, and these levels return to baseline within 3-12 weeks.
“Abstinent smokers compared to nonsmokers had higher levels of β2* nAChRs, which returned to baseline between 3-12 weeks, and elevated nAChR levels correlated with urge to smoke (Cosgrove et al., 2009; Mamede et al., 2007; Staley et al., 2006).”
From The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation (2012) · cites this paper as Staley et al., 2006
Studies of abstinent smokers show a relationship between β2* nAChR concentration and cravings to smoke to reduce withdrawal symptoms.
“results from studies of abstinent smokers showing a relationship between β2* nAChR concentration and cravings to smoke to reduce withdrawal symptoms (Staley et al., 2006).”
From The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation (2012) · cites this paper as Staley et al., 2006
Nicotine-induced up-regulation of nAChRs has been replicated in systems ranging from clonal cell lines to primary neurons in culture, mouse models, and smokers' brains.
“Nicotine-induced “up-regulation” has been replicated many times in systems ranging from clonal cell lines to primary neurons in culture, to mouse models, and to smokers’ brains (Breese et al., 1997; Court et al., 1998; Staley et al., 2006; Mukhin et al., 2008; Albuquerque et al., 2009; Lester et al., 2009).”
From Nicotine up-regulates α4β2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning (2011) · cites this paper as Staley et al., 2006
Human smokers show increased levels of nAChRs in functional magnetic resonance imaging and post mortem measurements.
“Human smokers also show increased levels of nAChRs in functional magnetic resonance imaging and post mortem measurements (6–9).”
From Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiometry. Implications for drug discovery (2009) · cites this paper as [9]
Nicotine abuse is associated with upregulation of the nicotinic receptor.
“Imaging studies of nicotine abuse report upregulation of the nicotinic receptor (Cosgrove et al., 2009; Mukhin et al., 2008; Staley et al., 2006; Wullner et al., 2008)”
From Imaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity (2014) · cites this paper as Staley et al., 2006
The magnitude of VT/fP differences between smokers and nonsmokers in this PET study was similar to that found in a recent SPECT study.
“The magnitude of the differences in VT/fP between smokers and nonsmokers was similar to that found in a recent SPECT study (28).”
From Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-<sup>18</sup>F-FA-85380 (2008) · cites this paper as [28]
The similar percentage differences in VT/fP measured with 2FA at 2 days after the last cigarette and with 5IA at about 7 days suggest that receptor density in smokers had already begun to decline by 7 days.
“That the percentage differences in VT/fP measured with 2FA at 2 d after the last smoked cigarette are similar to those assayed with 5IA at approximately 7 d after the last cigarette suggests that the receptor density in the smokers has already started to decline at 7 d.”
From Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-<sup>18</sup>F-FA-85380 (2008) · cites this paper as [28]
Taken together, results from two published SPECT studies and this PET study suggest that greater receptor density in smokers declines over the first 3 weeks after smoking cessation and approaches nonsmoker levels.
“Taken together, results from 2 published SPECT studies (28,30) and the current PET study suggest that the greater receptor density in smokers declines over the first 3 wk after smoking cessation and approaches the level observed in nonsmokers.”
From Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-<sup>18</sup>F-FA-85380 (2008) · cites this paper as [28]
Almost no difference in thalamic VT/fP was found in both the present PET study and the recent SPECT study.
“In that study and in the present PET study, almost no difference in VT/fP in the thalamus was demonstrated.”
From Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-<sup>18</sup>F-FA-85380 (2008) · cites this paper as [28]
The similarity in VT/fP changes between this PET study and the SPECT 5IA study was somewhat unexpected.
“As mentioned, the observed changes in VT/fP were similar to those observed with SPECT and 5IA as the radioligand (28). This similarity was somewhat unexpected.”
From Greater Nicotinic Acetylcholine Receptor Density in Smokers Than in Nonsmokers: A PET Study with 2-<sup>18</sup>F-FA-85380 (2008) · cites this paper as [28]
Protracted upregulation of nAChRs has been correlated with reduced ability to maintain abstinence in the clinical population.
“Previous studies suggest that the upregulated pool of nAChRs arising from long-term exposure to nicotine may drive elements of the nicotine withdrawal syndrome (Turner et al., 2011;Gould et al., 2012), and this protracted upregulation of nAChRs has been correlated with reduced ability to maintain abstinence in the clinical population (Staley et al., 2006).”
From Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors (2014) · cites this paper as Staley et al., 2006
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · cited 5× · see citing works
“The severity of nicotine dependence was assessed using the Fagerström Test for Nicotine Dependence (FTND) (Heatherton et al., 1991), nicotine withdrawal symptoms were assessed using the Minnesota Withdrawal Questionnaire (MWQ) (Hatsukami et al., 1984), and the urge to smoke (or craving) was assessed using the Urge to…”
MethodInfluentialSigns and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669 · cited 1× · see citing works
“Because the 2*-nAChR is the initial site of action of nicotine, adaptive changes during acute abstinence may be associated with nicotine withdrawal symptoms that emerge within hours after the last cigarette and persist for 3– 4 weeks (Hughes and Hatsukami, 1986).”
BackgroundPicciotto, M. R., Zoli, M., Rimondini, R., Léna, C., Marubio, L. M., Pich, E. M., Fuxe, K., & Changeux, J.-P. (1998) · Nature · doi:10.1038/34413 · Cited by 1,320 · cited 2× · see citing works
“Because the reinforcing properties of nicotine have been linked specifically to nAChRs that contain the 2 subunit ( 2*-nAChRs) (Picciotto et al., 1998), an understanding of the adaptive changes in 2*-nAChR number during acute abstinence and their relationship to behavioral correlates of tobacco…”
BackgroundSelf-citationGrant, B. F., Hasin, D. S., Chou, S. P., Stinson, F. S., & Dawson, D. A. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.11.1107 · Cited by 1,262 · cited 1× · see citing works
“Despite the well known health risks of tobacco smoking, 24.9% of the United States population continues to smoke (Grant et al., 2004).”
BackgroundInfluentialThe development and initial validation of a questionnaire on smoking urges
TIFFANY, S. T., & DROBES, D. J. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01732.x · Cited by 974 · cited 3× · see citing works
“Although most withdrawal symptoms resolve after a few days of abstinence, craving (i.e., the urge to smoke) is a prominent feature of nicotine dependence (Tiffany and Drobes, 1991) and is a primary factor associated with relapse (Killen et al., 1997).”
BackgroundMethodMolecular and cellular aspects of nicotine abuse
Dani, J. A., & Heinemann, S. (1996) · Neuron · doi:10.1016/s0896-6273(00)80112-9 · Cited by 605 · see citing works
Benwell, M. E. M., Balfour, D. J. K., & Anderson, J. M. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb10600.x · Cited by 551 · cited 1× · see citing works
“Postmortem studies of human brain have suggested that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999), and animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et…”
BackgroundNicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment
Marks, M., Pauly, Jr., Gross, S., Deneris, E., Hermans-Borgmeyer, I., Heinemann, S., & Collins, A. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02765.1992 · Cited by 551 · cited 3× · see citing works
“Greater 2*nAChR availability is not associated with changes in 2*-nAChR mRNA (Marks et al., 1992; Peng et al., 1994; Zhang et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al.”
BackgroundNicotinic Cholinergic Receptor Binding Sites in the Brain: Regulation in Vivo
Schwartz, R. D., & Kellar, K. J. (1983) · Science · doi:10.1126/science.6828889 · Cited by 479 · cited 1× · see citing works
“…that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999), and animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et al., 1983, 1985, 1992; Schwartz and Kellar, 1983).”
BackgroundEffects of chronic nicotine infusion on tolerance development and nicotinic receptors
Marks, M. J., Burch, J. B., & Collins, A. C. (1983) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21831-6 · Cited by 464 · cited 1× · see citing works
“…that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999), and animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et al., 1983, 1985, 1992; Schwartz and Kellar, 1983).”
BackgroundAssessing intrarater, interrater, and test-retest reliability of continuous measurements
Rousson, V., Gasser, T., & Seifert, B. (2002) · Statistics in Medicine · doi:10.1002/sim.1253 · Cited by 415 · cited 2× · see citing works
“The interclass coefficient to assess inter-rater reliability (Rousson et al., 2002) ranged between 0.”
BackgroundMethodInfluentialEffect of smoking history on [3H]nicotine binding in human postmortem brain
Breese, C. R., Marks, M. J., Logel, J., Adams, C. E., Sullivan, B., Collins, A. C., & Leonard, S. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36798-9 · Cited by 396 · see citing works
Peng, X., Gerzanich, V, Anand, R., Whiting, P. J., & Lindstrom, J. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09730-5 · Cited by 391 · cited 3× · see citing works
“Greater 2*nAChR availability is not associated with changes in 2*-nAChR mRNA (Marks et al., 1992; Peng et al., 1994; Zhang et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al.”
BackgroundIncreased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies
Perry, D. C., Dávila-Garcı́a, M. I., Stockmeier, C. A., & Kellar, K. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38304-1 · Cited by 362 · cited 1× · see citing works
“…brain have suggested that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999), and animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et al., 1983, 1985, 1992;…”
BackgroundChronic Exposure to Nicotine Upregulates the Human α4β2 Nicotinic Acetylcholine Receptor Function
Buisson, B., & Bertrand, D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-06-01819.2001 · Cited by 361 · cited 3× · see citing works
“…nAChR availability is not associated with changes in 2*-nAChR mRNA (Marks et al., 1992; Peng et al., 1994; Zhang et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al., 2005), but instead…”
BackgroundInfluentialThe paradox of nicotinic acetylcholine receptor upregulation by nicotine
Wonnacott, S. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90242-z · Cited by 357 · cited 1× · see citing works
“Functionally, greater 2*-nAChR availability in tobacco smokers likely represents greater numbers of desensitized and inactivated nAChRs (Wonnacott, 1990; Dani and Heinemann, 1996).”
BackgroundNicotine and the adolescent brain: insights from an animal model
Slotkin, T. (2002) · Neurotoxicology and Teratology · doi:10.1016/s0892-0362(02)00199-x · Cited by 284 · cited 1× · see citing works
“Although a species difference cannot be ruled out, this divergence may suggest that the ability of nicotine to regulate 2*-nAChR availability is age or sex dependent because the nonhuman primates were male adolescents and the smokers were male and female adults (Slotkin, 2002; Nguyen et al., 2003).”
BackgroundTime course study of the effects of chronic nicotine infusion on drug response and brain receptors
Marks, M. J., Stitzel, J. A., & Collins, A. C. (1985) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24213-6 · Cited by 265 · cited 1× · see citing works
“…that numbers of nAChRs are higher in smokers than in nonsmokers or former smokers (Benwell et al., 1988; Breese et al., 1997; Perry et al., 1999), and animals exposed to nicotine chronically exhibit increased levels of nAChRs in the brain (Marks et al., 1983, 1985, 1992; Schwartz and Kellar, 1983).”
BackgroundNicotine upregulates its own receptors through enhanced intracellular maturation
Sallette, J., Pons, S., Devillers-Thiery, A., Soudant, M., Prado de Carvalho, L., Changeux, J.-P., & Corringer, P. J. (2005) · Neuron · doi:10.1016/j.neuron.2005.03.029 · Cited by 261 · cited 5× · see citing works
“, 2003), enhanced maturation and transport through the secretory pathway to the cell membrane (Sallette et al., 2005), increased trans-”
BackgroundInfluentialThe Talairach Daemon a database server for talairach atlas labels
Lancaster, J. L., Summerlin, J. L., Rainey, L., Freitas, C., & Fox, P. T. (1997) · NeuroImage · Cited by 261 · see citing works
Tobacco withdrawal symptoms: An experimental analysis
Hatsukami, D. K., Hughes, J. R., Pickens, R. W., & Svikis, D. S. (1984) · Psychopharmacology · doi:10.1007/bf00427451 · Cited by 217 · see citing works
Nashmi, R., Dickinson, M. E., McKinney, S., Jareb, M., Labarca, C., Fraser, S. E., & Lester, H. A. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-37-11554.2003 · Cited by 188 · cited 2× · see citing works
“…it has also been suggested that the upregulation occurs as a consequence of increased assembly of 4 and 2 subunits in the endoplasmic reticulum (Nashmi et al., 2003), enhanced maturation and transport through the secretory path- way to the cell membrane (Sallette et al., 2005), increased…”
BackgroundWang, F., Nelson, M. E., Kuryatov, A., Olale, F., Cooper, J., Keyser, K., & Lindstrom, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.44.28721 · Cited by 187 · cited 1× · see citing works
“…endoplasmic reticulum (Nashmi et al., 2003), enhanced maturation and transport through the secretory path- way to the cell membrane (Sallette et al., 2005), increased transport to the membrane (Harkness and Millar, 2002), and/or decreased receptor turnover (Peng et al., 1994; Wang et al., 1998).”
BackgroundHariharan, M., VanNoord, T., & Greden, J. F. (1988) · Clinical Chemistry · doi:10.1093/clinchem/34.4.724 · Cited by 184 · see citing works
Roll, J. M., Higgins, S. T., & Badger, G. J. (1996) · Journal of Applied Behavior Analysis · doi:10.1901/jaba.1996.29-495 · Cited by 182 · cited 1× · see citing works
“Smokers (12 of 16) were assisted in quitting smoking using brief behavioral counseling based on Clinical Practice Guidelines and contingency management (Stitzer and Bigelow, 1985; Stitzer et al., 1986; Roll et al., 1996).”
Method5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors
Mukhin, A. G., Gündisch, D., Horti, A. G., Koren, A. O., Tamagnan, G., Kimes, A. S., Chambers, J., Vaupel, D. B., King, S. L., Picciotto, M. R., et al. (2000) · Molecular Pharmacology · doi:10.1124/mol.57.3.642 · Cited by 173 · cited 1× · see citing works
“Because nicotine competes with [ 123I]5-IA binding for binding to nAChRs (Mukhin et al., 2000), we first studied nonhuman primates chronically treated with nicotine to estimate the time interval necessary for smokers to abstain from smoking (before [ 123I]5-IA SPECT imaging) to ensure that residual…”
BackgroundSelf-citation(2001) · PubMed · Cited by 163 · see citing works
Nguyen, H. N., Rasmussen, B. A., & Perry, D. C. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.056408 · Cited by 148 · cited 2× · see citing works
“Although a species difference cannot be ruled out, this divergence may suggest that the ability of nicotine to regulate 2*-nAChR availability is age or sex dependent because the nonhuman primates were male adolescents and the smokers were male and female adults (Slotkin, 2002; Nguyen et al., 2003).”
BackgroundProspective study of risk factors for the initiation of cigarette smoking.
Killen, J. D., Robinson, T. N., Haydel, K. F., Hayward, C., Wilson, D. M., Hammer, L. D., Litt, I. F., & Taylor, C. B. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.65.6.1011 · Cited by 147 · cited 2× · see citing works
“Although most withdrawal symptoms resolve after a few days of abstinence, craving (i.e., the urge to smoke) is a prominent feature of nicotine dependence (Tiffany and Drobes, 1991) and is a primary factor associated with relapse (Killen et al., 1997).”
BackgroundCrooks, P. A., & Dwoskin, L. P. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00117-2 · Cited by 118 · cited 2× · see citing works
“, 2003) and that radiolabeled nicotine rapidly clears from brain (Crooks and Dwoskin, 1997; Crooks et al., 1997).”
BackgroundInfluentialProspective study of risk factors for the initiation of cigarette smoking.
Killen, J. D., Robinson, T. N., Haydel, K. F., et al. (1997) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.65.6.1011 · Cited by 113 · see citing works
Inhalation of vapor from black pepper extract reduces smoking withdrawal symptoms
Rose, J. E., & Behm, F. M. (1994) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)90160-0 · Cited by 102 · cited 1× · see citing works
“…and taste reception, these findings may suggest that occupancy of 2-nAChR by nicotine in the sensorimotor cortex may contribute to some of the sensory cues or “tasting of cigarettes” that has been shown to play an important role in the relief of craving and the urge to smoke (Rose and Behm, 1994).”
BackgroundTHE ACTIVATION OF CANNABINOID RECEPTORS IN STRIATONIGRAL GABAERGIC NEURONS INHIBITED GABA UPTAKE
Romero, J., de Miguel, R., Ramos, J. A., & Fernández‐Ruíz, J. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)01117-x · Cited by 95 · see citing works
Crooks, P. A., Li, M., & Dwoskin, L. P. (1997) · PubMed · Cited by 92 · see citing works
Benhammou, K., Lee, M., Strook, M. L., Sullivan, B. F., Logel, J., Raschen, K., Gotti, C., & Leonard, S. S. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00153-2 · Cited by 86 · cited 1× · see citing works
“*p values 0.00625 are significant after Bonferroni’s correction. unlike a previous study that demonstrated a positive correlation between [ 3H]nicotine binding to nAChRs on polymorphonuclear lymphocytes and the number of cigarettes smoked per day (Benhammou et al., 2000).”
ResultInfluentialCONTINGENT PAYMENT PROCEDURES FOR SMOKING REDUCTION AND CESSATION
Stitzer, M. L., Rand, C. S., Bigelow, G. E., & Mead, A. M. (1986) · Journal of Applied Behavior Analysis · doi:10.1901/jaba.1986.19-197 · Cited by 80 · cited 1× · see citing works
“Smokers (12 of 16) were assisted in quitting smoking using brief behavioral counseling based on Clinical Practice Guidelines and contingency management (Stitzer and Bigelow, 1985; Stitzer et al., 1986; Roll et al., 1996).”
MethodSallette, J., Bohler, S., Benoit, P., Soudant, M., Pons, S., Le Novère, N., Changeux, J.-P., & Corringer, P. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m308260200 · Cited by 80 · cited 1× · see citing works
“Although 2 subunits exist in several different combinations with 2, 3, 4, and 6 subunits, the 4 2 combination is most prevalent and also the most sensitive to upregulation by nicotine (Nguyen et al., 2003; Sallette et al., 2004).”
BackgroundDarsow, T., Booker, T. K., Piña-Crespo, J. C., & Heinemann, S. F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501157200 · Cited by 76 · cited 2× · see citing works
“…et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al., 2005), but instead appears to be attributable to occupancy of the nicotine binding site that bridges the / subunit interface of the…”
BackgroundHarkness, P. C., & Millar, N. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-23-10172.2002 · Cited by 74 · cited 1× · see citing works
“…endoplasmic reticulum (Nashmi et al., 2003), enhanced maturation and transport through the secretory path- way to the cell membrane (Sallette et al., 2005), increased transport to the membrane (Harkness and Millar, 2002), and/or decreased receptor turnover (Peng et al., 1994; Wang et al., 1998).”
BackgroundPietilä, K., Lähde, T., Attila, M., Ahtee, L., & Nordberg, A. (1998) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/pl00005152 · Cited by 67 · cited 1× · see citing works
“Nicotine was administered orally using the dose escalation paradigm described previously (Pietila et al., 1998).”
MethodMusachio, J. L., Villemagne, V. L., Scheffel, U. A., Dannals, R. F., Dogan, A. S., Yokoi, F., & Wong, D. F. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(98)00101-2 · Cited by 67 · cited 1× · see citing works
“With the recent development of [ 123I]5-IA-85380 ([ 123I]5-IA), a radioligand that has specificity for the agonist binding site on 2*- nAChRs (Musachio et al., 1998, 1999; Horti et al., 1999), it is now possible to measure this site in living smokers during acute abstinence from smoking and to…”
Schoedel, K. A., Sellers, E. M., Palmour, R., & Tyndale, R. F. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.96 · Cited by 64 · cited 2× · see citing works
“The apparent long residence time of nicotine on 2*-nAChR in brain is surprising given that the terminal half-life of nicotine is 1.6 h in macaques (Schoedel et al., 2003) and that radiolabeled nicotine rapidly clears from brain (Crooks and Dwoskin, 1997; Crooks et al., 1997).”
BackgroundInfluential(1998) · PubMed · Cited by 61 · see citing works
Significance of nonuniform attenuation correction in quantitative brain SPECT imaging.
Rajeevan, N., Zubal, I. G., Ramsby, S. Q., et al. (1998) · PubMed · Cited by 60 · see citing works
Self-citationMusachio, J. L., Scheffel, U., Finley, P. A., Zhan, Y., Mochizuki, T., Wagner, H. N., & Dannals, R. F. (1998) · Life Sciences · doi:10.1016/s0024-3205(98)00180-5 · Cited by 57 · cited 1× · see citing works
“With the recent development of [ 123I]5-IA-85380 ([ 123I]5-IA), a radioligand that has specificity for the agonist binding site on 2*- nAChRs (Musachio et al., 1998, 1999; Horti et al., 1999), it is now possible to measure this site in living smokers during acute abstinence from smoking and to…”
J. Vainio, R. K. T. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110043095 · Cited by 51 · cited 1× · see citing works
“The rapid pharmacokinetics were observed, however, after a single administration of a trace dose of intravenous nicotine, and the accumulation of nicotine and/or metabolites (Vainio and Tuominen, 2001) in brain may differ with protracted and repeated nicotine administration.”
BackgroundStitzer, M. L., & Bigelow, G. E. (1985) · Addictive Behaviors · doi:10.1016/0306-4603(85)90030-9 · Cited by 50 · cited 1× · see citing works
“Smokers (12 of 16) were assisted in quitting smoking using brief behavioral counseling based on Clinical Practice Guidelines and contingency management (Stitzer and Bigelow, 1985; Stitzer et al., 1986; Roll et al., 1996).”
MethodHorti, A. G., Koren, A. O., Lee, K. S., Mukhin, A. G., Vaupel, D. B., Kimes, A. S., Stratton, M., & London, E. D. (1999) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(98)00086-9 · Cited by 48 · cited 1× · see citing works
“…of [ 123I]5-IA-85380 ([ 123I]5-IA), a radioligand that has specificity for the agonist binding site on 2*- nAChRs (Musachio et al., 1998, 1999; Horti et al., 1999), it is now possible to measure this site in living smokers during acute abstinence from smoking and to determine the relationship…”
BackgroundSelf-citationIn vivo specific binding of [3H]-1-nicotine in the mouse brain
Broussolle, E. P., Wong, D. F., Fanelli, R. J., & London, E. D. (1989) · Life Sciences · doi:10.1016/0024-3205(89)90340-8 · Cited by 47 · cited 1× · see citing works
“Nicotine is highly lipophilic and, when radiolabeled, demonstrates very high levels of nonspecific brain uptake (Broussolle et al., 1989; Muzic et al., 1998).”
BackgroundSelf-citationRush, R., Kuryatov, A., Nelson, M. E., & Lindstrom, J. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.6.1416 · Cited by 40 · cited 1× · see citing works
“The relationship between greater 2*-nAChR availability and nAChR function may vary in a region-dependent manner attributable to different subunit combinations that demonstrate increased agonist binding but differ in the effects on function (Rush et al., 2002).”
(2005) · PubMed · Cited by 40 · see citing works
Self-citationZhang, X., Gong, Z.-H., Hellström-Lindahl, E., & Nordberg, A. (1995) · Neuroreport · doi:10.1097/00001756-199501000-00022 · Cited by 36 · cited 1× · see citing works
“Greater 2*- nAChR availability is not associated with changes in 2*-nAChR mRNA (Marks et al., 1992; Peng et al., 1994; Zhang et al., 1994) protein synthesis (Buisson and Bertrand, 2001), rate of receptor internalization, postendocytic trafficking, or lysosomal degradation (Darsow et al., 2005), but…”
BackgroundZoghbi, S. S., Tamagnan, G. D., Fujita, M., Baldwin, R. M., Al‐Tikriti, M. S., Amici, L., Seibyl, J. P., & Innis, R. B. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00188-8 · Cited by 29 · cited 2× · see citing works
“Three SPECT scans (30 min each) were obtained between 6 and 8 h of infusion, and plasma samples were collected immediately before and after the scan to quantify total parent and the free fraction of parent tracer in plasma ( f1, free fraction) (Zoghbi et al., 2001).”
MethodSelf-citation5-Iodo-A-85380, an α4β2 Subtype-Selective Ligand for Nicotinic Acetylcholine Receptors
Mukhin, A. G., Gündisch, D., Horti, A. G., Koren, A. O., Tamagnan, G. D., Kimes, A. S., Chambers, J., Vaupel, D. B., King, S. L., Picciotto, M. R., et al. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)26432-4 · Cited by 13 · see citing works
Self-citationSPECT imaging with the D4 receptor antagonist L-750,667 in nonhuman primate brain
Staley, J. K., Tamagnan, G. D., Baldwin, R. M., et al. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00129-3 · Cited by 12 · cited 2× · see citing works
“Nonhuman primates were imaged using methods described previously (Staley et al., 2000).”
MethodSelf-citationNeurochemical Substrates of Habitual Tobacco Smoking
Krishnan‐Sarin, S., Staley, J. K., & Esterlis, I. (2007) · CRC Press eBooks · doi:10.1201/9781420054422.ch3 · Cited by 1 · see citing works
Self-citationLurito (2000) · doi:10.1002/1097-0193(200007)10:3
Flagged first, then by citations
7 of the 64 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Structural and functional diversity of native brain neuronal nicotinic receptors
Gotti, C., Clementi, F., Fornari, A., Gaimarri, A., Guiducci, S., Manfredi, I., Moretti, M., Pedrazzi, P., Pucci, L., & Zoli, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.024 · Cited by 469 · see citing works
“have high β2* receptor levels for at least seven days after stopping smoking [123].”
BackgroundPICCIOTTO, M., ADDY, N., MINEUR, Y., & BRUNZELL, D. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.12.005 · Cited by 451 · see citing works
“Indeed, this hypothesis suggests that the increased depressive symptoms observed in some patients following acute cessation from smoking might be explained by the fact that the clearance of nicotine following smoking cessation coupled with persistent nAChR upregulation (Staley et al., 2006) results in increased abilit…”
BackgroundInfluentialSelf-citationMolecular tracers for the PET and SPECT imaging of disease
Pimlott, S. L., & Sutherland, A. J. (2010) · Chemical Society Reviews · doi:10.1039/b922628c · Cited by 379 · see citing works
Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis
Mineur, Y. S., & Picciotto, M. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.004 · Cited by 277 · see citing works
Self-citationNeural substrates of abstinence-induced cigarette cravings in chronic smokers
Wang, Z., Faith, M., Patterson, F., Tang, K., Kerrin, K., Wileyto, E. P., Detre, J. A., & Lerman, C. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2966-07.2007 · Cited by 256 · see citing works
Why do patients with schizophrenia smoke?
Winterer, G. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283366643 · Cited by 238 · see citing works
Smoking, quitting, and psychiatric disease: A review
Aubin, H., Rollema, H., Svensson, T. H., & Winterer, G. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.06.007 · Cited by 231 · see citing works
Varenicline improves mood and cognition during smoking abstinence
Patterson, F., Jepson, C., Strasser, A. A., Loughead, J., Perkins, K. A., Gur, R. C., Frey, J. M., Siegel, S., & Lerman, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.028 · Cited by 222 · see citing works
Smoking, nicotine and neuropsychiatric disorders
Döme, P., Lazáry, J., Kalapos, M. P., & Rihmer, Z. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.07.013 · Cited by 215 · see citing works
“…in humans have also confirmed both the upregulation of a4b2 receptors after chronic NIC administration (smoking) and the termination of upregulation after approximately 21 days of smoking cessation (Mamede et al., 2007; Staley et al., 2006; Wullner et al., 2008; Kassiou et al., 2001).”
Backgroundα6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 194 · see citing works
“Long-term nicotine administration, delivered in multiple forms (injection, minipump, drinking water, or self-administration), increases the numbers of 4 2* binding sites throughout the brain in experimental animal models and humans (Marks et al., 1983; Schwartz and Kellar, 1983; Benwell et al., 1988; Perry et al., 199…”
BackgroundSex Differences in the Brain's Dopamine Signature of Cigarette Smoking
Cosgrove, K. P., Wang, S., Kim, S., McGovern, E., Nabulsi, N., Gao, H., Labaree, D., Tagare, H., Sullivan, J. M., & Morris, E. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.3661-14.2014 · Cited by 168 · see citing works
“Overnight abstinence was confirmed with breath CO levels 10 ppm. Plasma nicotine and cotinine levels were measured as previously described (Staley et al., 2006).”
Self-citationSrinivasan, R., Pantoja, R., Moss, F. J., Mackey, E. D. W., Son, C. D., Miwa, J., & Lester, H. A. (2011) · Journal of General Physiology · doi:10.1085/jgp.201010532 · Cited by 169 · see citing works
McLaughlin, I., Dani, J. A., & De Biasi, M. (2015) · Current Topics in Behavioral Neurosciences · doi:10.1007/978-3-319-13482-6_4 · Cited by 173 · see citing works
“Using a radioligand with specificity for β2containing nAChRs, which enabled the use of single-photon emission computed tomography (SPECT) (Staley et al. 2006), it was found that chronic smokers have more cortical, striatal, and cerebellar β2* nAChRs than non-smokers (Staley et al.”
BackgroundInfluentialImaging addiction: D2 receptors and dopamine signaling in the striatum as biomarkers for impulsivity
Trifilieff, P., & Martinez, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.06.031 · Cited by 171 · see citing works
“Imaging studies of nicotine abuse report upregulation of the nicotinic receptor (Cosgrove et al., 2009; Mukhin et al., 2008; Staley et al., 2006; Wullner et al., 2008) and an imaging study of opiate abusers showed upregulation of the mu receptor (Zubieta et al., 2000).”
BackgroundCognitive function during nicotine withdrawal: Implications for nicotine dependence treatment
Ashare, R. L., Falcone, M., & Lerman, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.034 · Cited by 170 · see citing works
“Further, following cessation of smoking, unbound nAChRs are present at a higher level for as long as one week, and nAChR binding availability has been associated with self-reported withdrawal and craving (Cosgrove et al., 2009; Staley et al., 2006).”
Dual role of nicotine in addiction and cognition: A review of neuroimaging studies in humans
Jasinska, A. J., Zorick, T. S., Brody, A. L., & Stein, E. A. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.02.015 · Cited by 163 · see citing works
“…2-FA and 5-IA, have demonstrated up-regulation of available a4b2* nAChRs in smokers compared to non-smoking participants in brain regions other than the thalamus (Brody et al., 2012; Cosgrove et al., 2009, 2012; Mamede et al., 2007; Mukhin et al., 2008; Staley et al., 2006; Wullner et al., 2008).”
InfluentialLester, H. A., Xiao, C., Srinivasan, R., Son, C. D., Miwa, J., Pantoja, R., Banghart, M. R., Dougherty, D. A., Goate, A. M., & Wang, J. C. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9090-7 · Cited by 163 · see citing works
Cosgrove, K. P., Batis, J., Bois, F., Maciejewski, P. K., Esterlis, I., Kloczynski, T., Stiklus, S., Krishnan-Sarin, S., O’Malley, S., Perry, E., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.41 · Cited by 159 · see citing works
Self-citationGenetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction
Mineur, Y. S., & Picciotto, M. R. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.010 · Cited by 138 · see citing works
“Upregulation is still observed in abstinent smokers at least 14 days after smoking cessation [63], and tolerance can also be observed without changes in nicotine binding [64].”
BackgroundSelf-citationConti, D. V., Lee, W., Li, D., Liu, J., Van Den Berg, D., Thomas, P. D., Bergen, A. W., Swan, G. E., Tyndale, R. F., Benowitz, N. L., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn181 · Cited by 136 · see citing works
Mukhin, A. G., Kimes, A. S., Chefer, S. I., Matochik, J. A., Contoreggi, C. S., Horti, A. G., Vaupel, D. B., Pavlova, O., & Stein, E. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.050716 · Cited by 135 · see citing works
“As mentioned, the observed changes in VT/fP were similar to those observed with SPECT and 5IA as the radioligand (28).”
ResultAcetylcholine receptors in dementia and mild cognitive impairment
Sabri, O., Kendziorra, K., Wolf, H., Gertz, H., & Brust, P. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0701-1 · Cited by 127 · see citing works
“the effects of tobacco use on nicotinic receptor saturation and availability [86–91].”
BackgroundNeurobiological Mechanisms of Nicotine Reward and Aversion
Wills, L. P., Ables, J. L., Braunscheidel, K. M., Caligiuri, S. P. B., Elayouby, K. S., Fillinger, C., Ishikawa, M., Moen, J. K., & Kenny, P. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000299 · Cited by 126 · see citing works
“Nicotine-induced upregulation of nAChR expression has been detected in the brains of rodents and human smokers (Marks et al., 1983; Breese et al., 1997; Staley et al., 2006; Nashmi et al., 2007).”
BackgroundYoung, J. W., & Geyer, M. A. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.031 · Cited by 123 · see citing works
“nAChRs and commonly used in smoking studies [81,82].”
Molecules and circuits involved in nicotine addiction: The many faces of smoking
Picciotto, M. R., & Mineur, Y. S. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.028 · Cited by 117 · see citing works
“However, chronic smoking also leads to long-term upregulation of high affinity nAChRs containing the b2 subunit (Staley et al., 2006), potentially increasing nAChR activity once nicotine-induced desensitization is relieved following abstinence.”
BackgroundSelf-citationSaricicek, A., Esterlis, I., Maloney, K. H., Mineur, Y. S., Ruf, B. M., Muralidharan, A., Chen, J. I., Cosgrove, K. P., Kerestes, R., Ghose, S., et al. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11101546 · Cited by 118 · see citing works
“SPECT imaging protocol was conducted as described previously (34).”
BackgroundMethodSelf-citationSutherland, M. T., Riedel, M. C., Flannery, J. S., Yanes, J. A., Fox, P. T., Stein, E. A., & Laird, A. R. (2016) · Behavioral and Brain Functions · doi:10.1186/s12993-016-0100-5 · Cited by 114 · see citing works
“Widespread upregulation of nAChRs, likely related to receptor desensitization from nicotine exposure, has been observed among smokers [70, 71] and, conversely, smoking cessation associated with decreases in regional nAChR densities [72].”
BackgroundLong-term effects of chronic nicotine exposure on brain nicotinic receptors
Besson, M., Granon, S., Mameli-Engvall, M., Cloëz-Tayarani, I., Maubourguet, N., Cormier, A., Cazala, P., David, V., Changeux, J., & Fauré, P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702698104 · Cited by 113 · see citing works
Molecular and Cellular Mechanisms of Action of Nicotine in the CNS
Barik, J., & Wonnacott, S. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_7 · Cited by 108 · see citing works
Up-regulation of nicotinic acetylcholine receptors in menthol cigarette smokers
Brody, A. L., Mukhin, A. G., Charite, J. L., Ta, K., Farahi, J. B., Sugar, C. A., Mamoun, M. S., Vellios, E. E., Archie, M. M., Kozman, M., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001022 · Cited by 106 · see citing works
“This issue of smokers using nicotine/tobacco during the abstinence period of a brain imaging study has also been reported in prior studies (Esterlis et al. 2010a ; Staley et al. 2006), presumably related to difficulty in having tobaccodependent smokers remain abstinent for a prolonged period.”
BackgroundMethodResultInfluentialInside-out neuropharmacology of nicotinic drugs
Henderson, B. J., & Lester, H. A. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.01.022 · Cited by 102 · see citing works
“Upregulation of AChRs in humans has been detected by comparing [3H]nicotine binding to postmortem brains of smokers and non-smokers and in vivo by fMRI or PET imaging (Benwell et al., 1988; Breese et al., 1997; Brody et al., 2013, 2008, 2011, 2006; Cosgrove et al., 2009; Jasinska et al., 2014; Mamede et al., 2007; Per…”
Cosgrove, K. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1465 · Cited by 105 · see citing works
Self-citationPerry, D. C., Mao, D., Gold, A. B., McIntosh, J. M., Pezzullo, J. C., & Kellar, K. J. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121228 · Cited by 106 · see citing works
“Recently, increased nAChRs were imaged in living human subjects who smoked (Staley et al., 2006).”
BackgroundPerkins, K. A., Karelitz, J. L., Conklin, C. A., Sayette, M. A., & Giedgowd, G. E. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.12.017 · Cited by 105 · see citing works
Nicotine patch therapy prior to quitting smoking: a meta‐analysis
Shiffman, S., & Ferguson, S. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02138.x · Cited by 94 · see citing works
“While the terminal half-life of nicotine is ~ 2 hours [14], a recent imaging study [15] suggests that nicotine may reside on the nicotine receptor for a longer duration.”
In vivo Brain Imaging of Human Exposure to Nicotine and Tobacco
Sharma, A., & Brody, A. L. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-69248-5_6 · Cited by 88 · see citing works
“In a recent study, Staley et al. (2006) hypothesized that an abnormally high number of β2nAChRs in early abstinence may be responsible for continued tobacco usage.”
Temporal Change in Human Nicotinic Acetylcholine Receptor After Smoking Cessation: 5IA SPECT Study
Mamede, M., Ishizu, K., Ueda, M., Mukai, T., Iida, Y., Kawashima, H., Fukuyama, H., Togashi, K., & Saji, H. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.043471 · Cited by 90 · see citing works
“The authors noted that after 6.8 6 1.9 d of tobacco abstinence, the uptake of 123I-5IA increased significantly throughout the cerebral cortex (26%;36%) in smokers ( 13 ).”
BackgroundMethodResultInfluentialOvarian Hormones and Drug Abuse
Maria, M. M. M., Flanagan, J. C., & Brady, K. T. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0511-7 · Cited by 81 · see citing works
Henderson, B. J., Wall, T. R., Henley, B. M., Kim, C. H., Nichols, W. A., Moaddel, R., Xiao, C., & Lester, H. A. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4194-15.2016 · Cited by 79 · see citing works
“…using 2-[ 18F]fluoro-A-85380 (binds 2* nAChRs) indicate that 2* nAChR upregulation in humans is saturated with only a few cigarettes smoked daily (Staley et al., 2006), probably because 2* nAChRs are saturated even at nicotine concentrations found in low-nicotine cigarettes (Brody et al., 2009).”
MethodUnderstanding the habenula: A major node in circuits regulating emotion and motivation
Ables, J. L., Park, K., & Ibáñez-Tallon, I. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106734 · Cited by 76 · see citing works
Mineur, Y. S., Cahuzac, E. L. M., Mose, T. N., Bentham, M. P., Plantenga, M. E., Thompson, D. C., & Picciotto, M. R. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0024-x · Cited by 71 · see citing works
“One consequence of chronic nicotine exposure through tobacco smoke is an upregulation of high-affinity β2-containing nAChRs throughout the brain [13].”
BackgroundSelf-citationPharmacological chaperoning of nAChRs: A therapeutic target for Parkinson's disease
Srinivasan, R., Henderson, B. J., Lester, H. A., & Richards, C. I. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.02.005 · Cited by 67 · see citing works
Greenbaum, L., & Lerer, B. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.59 · Cited by 73 · see citing works
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning
Gould, T. J., & Leach, P. T. (2013) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.08.004 · Cited by 68 · see citing works
Cigarette craving is associated with blunted reward processing in nicotine-dependent smokers
Peechatka, A. L., Whitton, A. E., Farmer, S. L., Pizzagalli, D. A., & Janes, A. C. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.07.015 · Cited by 67 · see citing works
Quaak, M., van Schayck, O. C. P., Knaapen, A. M., & van Schooten, F. (2009) · European Respiratory Journal · doi:10.1183/09031936.00056908 · Cited by 65 · see citing works
Brody, A. L., Hubert, R., Enoki, R., Garcia, L. Y., Mamoun, M. S., Okita, K., London, E. D., Nurmi, E. L., Seaman, L. C., & Mandelkern, M. A. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.48 · Cited by 63 · see citing works
“…would occur globally throughout the brain, as prior research by our group (Brody et al, 2006a, 2009a, 2011, 2013) and others (Cosgrove et al, 2009; Staley et al, 2006) demonstrates widespread effects of smoking when studying systems (eg, the nicotinic cholinergic system) that are widely…”
BackgroundResultSelf-citationAge-related decline in nicotinic receptor availability with [123I]5-IA-85380 SPECT
Mitsis, E. M., Cosgrove, K. P., Staley, J. K., Bois, F., Frohlich, E. B., Tamagnan, G. D., Estok, K. M., Seibyl, J. P., & van Dyck, C. H. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.008 · Cited by 65 · see citing works
Self-citationRodent models for nicotine withdrawal
Chellian, R., Behnood‐Rod, A., Bruijnzeel, D. M., Wilson, R., Pandy, V., & Bruijnzeel, A. W. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211005629 · Cited by 68 · see citing works
“In humans, smoking leads to an upregulation of α4β2* nAChRs in the brain (Benwell et al., 1988; Staley et al., 2006).”
BackgroundHannestad, J. O., Cosgrove, K. P., DellaGioia, N. F., Perkins, E., Bois, F., Bhagwagar, Z., Seibyl, J. P., McClure-Begley, T. D., Picciotto, M. R., & Esterlis, I. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.04.004 · Cited by 63 · see citing works
“Previous studies revealed that 1 week of smoking cessation is required for all nicotine to leave the brain to accurately quantify β2*nAChR availability (25).”
BackgroundSelf-citationEffects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans
Mathalon, D. H., Ahn, K.-H., Perry, E. B., Cho, H. S., Roach, B. J., Blais, R. K., Bhakta, S. G., Ranganathan, M., Ford, J. M., & D’Souza, D. C. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00003 · Cited by 64 · see citing works
“Plasma nicotine concentrations were assayed using reversed-phase highperformance liquid chromatography (HPLC) based on a modification of a previously described method (115, 116).”
MethodSelf-citationAddiction‐related neuroadaptations following chronic nicotine exposure
Wills, L., & Kenny, P. J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15356 · Cited by 61 · see citing works
Lower β2*-Nicotinic Acetylcholine Receptor Availability in Smokers With Schizophrenia
D’Souza, D. C., Esterlis, I., Carbuto, M., Krasenics, M., Seibyl, J. P., Bois, F., Pittman, B. P., Ranganathan, M., Cosgrove, K., & Staley, J. K. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.11020189 · Cited by 61 · see citing works
Self-citationChang, D., Zhang, J., Peng, W., Shen, Z., Gao, X., Du, Y.-H., Ge, Q., Song, D., Shang, Y., & Wang, Z. (2018) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2018.00344 · Cited by 48 · see citing works
“Due to the chronic nAchRs upregulation, abstinence from nicotine will dramatically increase the availability of unbound α4β2 nAchRs, which in turn leads to smoking craving (Staley et al., 2006) and the subsequent smoking relapse.”
BackgroundSabri, O., Becker, G., Meyer, P., Hesse, S., Wilke, S., Graef, S., Patt, M., Luthardt, J., Wagenknecht, G., Hoepping, A., et al. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.05.065 · Cited by 59 · see citing works
“, 2006), nicotine dependence (Mukhin et al., 2008; Staley et al., 2006), major depressive disease (Saricicek et al.”
Nicotinic Receptor Contributions to Smoking: Insights from Human Studies and Animal Models
Brunzell, D. H., Stafford, A. M., & Dixon, C. I. (2015) · Current Addiction Reports · doi:10.1007/s40429-015-0042-2 · Cited by 58 · see citing works
Therapeutic vaccines against tobacco addiction
Fahim, R. E. F., Kessler, P., & Kalnik, M. W. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.13 · Cited by 57 · see citing works
Nicotine Dependence: Biology, Behavior, and Treatment
Ray, R., Schnoll, R. A., & Lerman, C. E. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.041707.160511 · Cited by 57 · see citing works
“The same study demonstrated that abstinence-induced increases in the numbers of unbound receptors correlated with smoking urges (26).”
BackgroundLindroos, R., Dorst, M. C., Du, K., Filipović, M., Keller, D. X., Ketzef, M., Kozlov, A., Kumar, A., Lindahl, M., Nair, A. G., et al. (2018) · Frontiers in Neural Circuits · doi:10.3389/fncir.2018.00003 · Cited by 44 · see citing works
“As ACh and DA Frontiers in Neural Circuits | www.frontiersin.org 4 February 2018 | Volume 12 | Article 3 are believed to serve antagonistic roles, increasing cholinergic tone through acetylcholinesterase inhibitors can suppress addictive symptoms (Staley et al., 2006).”
BackgroundGould, T. J., Portugal, G. S., André, J. M., Tadman, M. P., Marks, M. J., Kenney, J. W., Yildirim, E., & Adoff, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.003 · Cited by 56 · see citing works
“Abstinent smokers compared to nonsmokers had higher levels of b2* nAChRs, which returned to baseline between 3e12 weeks, and elevated nAChR levels correlated with urge to smoke (Cosgrove et al., 2009; Mamede et al., 2007; Staley et al., 2006).”
The nicotinic cholinergic system function in the human brain
Nees, F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.021 · Cited by 53 · see citing works
Esterlis, I., Ranganathan, M., Bois, F., Pittman, B. P., Picciotto, M. R., Shearer, L., Anticevic, A., Carlson, J., Niciu, M. J., Cosgrove, K., et al. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.11.001 · Cited by 54 · see citing works
Self-citationRegional metabolite levels and turnover in the awake rat brain under the influence of nicotine
Wang, J., Jiang, L., Jiang, Y., Ma, X., Chowdhury, G. M. I., & Mason, G. F. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06684.x · Cited by 53 · see citing works
“Though there are some differences, such as a subunit distribution in the thalamus, reviewed previously (Spurden et al. 1997), they are in general similarly distributed in rats and humans (Spurden et al. 1997; Turner and Kellar 2005; Staley et al. 2006).”
BackgroundEsterlis, I., Hannestad, J. O., Perkins, E., Bois, F., D’Souza, D. C., Tyndale, R. F., Seibyl, J. P., Hatsukami, D., Cosgrove, K., & O’Malley, S. S. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12060793 · Cited by 55 · see citing works
Self-citationThe Molecular and Cellular Neurobiology of Nicotine Abuse in Schizophrenia
Mobascher, A., & Winterer, G. (2008) · Pharmacopsychiatry · doi:10.1055/s-2008-1081463 · Cited by 50 · see citing works
Poorthuis, R. B., & Mansvelder, H. D. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.003 · Cited by 48 · see citing works
“Imaging studies showed that receptors remain upregulated even in the abstinence of smoking for more than seven days [139].”
BackgroundNicotine and alcohol: the role of midbrain dopaminergic neurons in drug reinforcement
Morel, C., Montgomery, S. E., & Han, M. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14160 · Cited by 45 · see citing works
Kimes, A. S., Chefer, S. I., Matochik, J. A., Contoreggi, C. S., Vaupel, D. B., Stein, E. A., & Mukhin, A. G. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.09.015 · Cited by 49 · see citing works
In vivo measurement of nicotinic acetylcholine receptors with [18F]norchloro‐fluoro‐homoepibatidine
Brust, P., Patt, J. T., Deuther‐Conrad, W., Becker, G., Patt, M., Schildan, A., Sorger, D., Kendziorra, K., Meyer, P., Steinbach, J., et al. (2007) · Synapse · doi:10.1002/syn.20480 · Cited by 46 · see citing works
“…nicotinic receptor saturation and availability in volunteers (Brody et al., 2006; Gallezot et al., 2005; Kimes et al., 2003; Shumway et al., 2007; Staley et al., 2005, 2006), only a few studies were performed in patients which show alterations in nAChRs densities in frontal lobe epilepsy (Picard…”
BackgroundPathophysiology of nAChRs: Limbic circuits and related disorders
Mineur, Y. S., Soares, A. R., Etherington, I. M., Abdulla, Z. I., & Picciotto, M. R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106745 · Cited by 42 · see citing works
Self-citationMenossi, H. S., Goudriaan, A. E., Périco, C. D. A.-M., Nicastri, S., de Andrade, A. G., D’Elia, G., Li, C. R., & Castaldelli-Maia, J. M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0092-8 · Cited by 43 · see citing works
“In abstinent smokers, the level of free a4b2 nAChRs is associated with the desire to smoke [29].”
BackgroundBrain Nicotinic Acetylcholine Receptor Availability and Response to Smoking Cessation Treatment
Brody, A. L., Mukhin, A. G., Mamoun, M. S., Luu, T., Neary, M. K., Liang, L., Shieh, J., Sugar, C. A., Rose, J. E., & Mandelkern, M. A. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.138 · Cited by 42 · see citing works
Nicotinic Receptors, Memory, and Hippocampus
Kutlu, M. G., & Gould, T. J. (2015) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-13665-3_6 · Cited by 41 · see citing works
Verplaetse, T. L., Morris, E. D., McKee, S. A., & Cosgrove, K. (2018) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2018.04.004 · Cited by 41 · see citing works
Self-citationImaging Receptor Changes in Human Drug Abusers
Cosgrove, K. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_24 · Cited by 40 · see citing works
“Specifically, there is a higher availability of b2*-nAChRs in tobacco smokers during acute abstinence compared to never smokers in the cerebellum, striatum, and throughout the cortex (Mukhin et al. 2008; Staley et al. 2006).”
BackgroundSelf-citationLewis, A. S., & Picciotto, M. R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3126-5 · Cited by 38 · see citing works
“This study was done in recently abstinent (~1 week) tobacco smokers, since the nicotine from tobacco competes with the radiotracer, and previous studies have shown that there is still upregulation of nAChRs at this time point in smokers without psychiatric illness (Staley et al. 2006).”
InfluentialSelf-citationTobacco smoking and dopaminergic function in humans: a meta-analysis of molecular imaging studies
Ashok, A. H., Mizuno, Y., & Howes, O. D. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05196-1 · Cited by 36 · see citing works
“Moreover, molecular imaging studies have shown that occupancy of the nicotinic acetylcholine receptor is associated with the subjective hedonic response of smoking (Brody et al. 2009a, 2011, 2006a, 2014, 2013; Cosgrove et al. 2009a; Cosgrove et al. 2012; Dubroff et al. 2015; Lotfipour et al. 2012; Staley et al. 2006).”
BackgroundD’Souza, D. C., Ahn, K.-H., Bhakta, S. G., Elander, J., Singh, N. M., Nadim, H., Jatlow, P. I., Suckow, R. F., Pittman, B. P., & Ranganathan, M. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.009 · Cited by 38 · see citing works
Self-citationLong-Term Upregulation of Protein Kinase A and Adenylate Cyclase Levels in Human Smokers
Hope, B. T., Nagarkar, D. R., Leonard, S. S., & Wise, R. A. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.3661-06.2007 · Cited by 37 · see citing works
Neuropeptide systems and new treatments for nicotine addiction
Bruijnzeel, A. W. (2017) · Psychopharmacology · doi:10.1007/s00213-016-4513-5 · Cited by 36 · see citing works
“Tobacco use in humans and chronic nicotine or tobacco smoke exposure in rodents leads to an upregulation of nAChRs in the brain (Benwell et al. 1988; Marks et al. 1983; Small et al. 2010; Staley et al. 2006).”
Cosgrove, K., Esterlis, I., McKee, S. A., Bois, F., Alagille, D., Tamagnan, G. D., Seibyl, J. P., Krishnan‐Sarin, S., & Staley, J. K. (2010) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntq040 · Cited by 37 · see citing works
Self-citationKnott, V., Millar, A., McIntosh, J. F., Shah, D. K., Fisher, D. J., Blais, C. M., Ilivitsky, V., & Horn, E. (2011) · Biological Psychology · doi:10.1016/j.biopsycho.2011.06.012 · Cited by 37 · see citing works
Esterlis, I., Cosgrove, K., Batis, J. C., Bois, F., Stiklus, S. M., Perkins, E., Seibyl, J. P., Carson, R. E., & Staley, J. K. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.072447 · Cited by 36 · see citing works
Self-citationMcClure‐Begley, T. D., Papke, R. L., Stone, K. L., Stokes, C. A., Levy, A. D., Gelernter, J. E., Xie, P., Lindstrom, J. M., & Picciotto, M. R. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.209767 · Cited by 26 · see citing works
“Upregulation of a4b2* nAChRs by long-term exposure to nicotine has been suggested to play a role in the development/ maintenance of nicotine dependence and has been observed repeatedly both in vitro and in vivo in rodents and human smokers (Staley et al., 2006; Lester et al., 2009).”
BackgroundSelf-citationJørgensen, K. N., Psychol, C., Skjærvø, I., Mørch-Johnsen, L. E., Haukvik, U. K., Lange, E. H., Melle, I. S., Andreassen, O. A., & Agartz, I. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140163 · Cited by 32 · see citing works
Hussmann, G. P., Turner, J. R., Lomazzo, E., Venkatesh, R., Cousins, V., Xiao, Y., Yasuda, R. P., Wolfe, B. B., Perry, D. C., Rezvani, A. H., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.198085 · Cited by 34 · see citing works
“441 1992; Mao et al., 2008; Moretti et al., 2010; Marks et al., 2011), and based on the limited spectrum of the radioligand used to image the receptors in vivo that is also probably the case in primate brains (Kassiou et al., 2001; Staley et al., 2006; Wüllner et al., 2008).”
InfluentialBrody, A. L., Gehlbach, D. L., Garcia, L. Y., Enoki, R., Hoh, C. K., Vera, D. R., Kotta, K. K., London, E. D., Okita, K., Nurmi, E. L., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5077-3 · Cited by 32 · see citing works
Self-citationNeurobiological and Neurophysiological Mechanisms Underlying Nicotine Seeking and Smoking Relapse
Schmidt, H. D., Rupprecht, L. E., & Addy, N. (2018) · Complex Psychiatry · doi:10.1159/000494799 · Cited by 32 · see citing works
Archie, S. R., Sharma, S., Burks, E., & Abbruscato, T. J. (2022) · NeuroToxicology · doi:10.1016/j.neuro.2022.02.002 · Cited by 32 · see citing works
Treatment for Tobacco Dependence: Effect on Brain Nicotinic Acetylcholine Receptor Density
Brody, A. L., Mukhin, A. G., Shulenberger, S., Mamoun, M. S., Kozman, M., Phuong, J., Neary, M. K., Luu, T., & Mandelkern, M. A. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.53 · Cited by 33 · see citing works
“…(Brody et al, 2013) and other studies linking nicotine (Marks et al, 2011; Yates et al, 1995; Zhang et al, 2002) and cigarette smoke (Mamede et al, 2007; Mukhin et al, 2008; Staley et al, 2006; Wullner et al, 2008) exposure with upregulation of a4b2* nAChRs in brain regions other than the thalamus.”
BackgroundFood Addiction and Tobacco Use Disorder: Common Liability and Shared Mechanisms
Zawertailo, L. A., Attwells, S., deRuiter, W. K., Le, T. L., Dawson, D., & Selby, P. L. (2020) · Nutrients · doi:10.3390/nu12123834 · Cited by 31 · see citing works
“Preclinical studies assessing nicotine administration in animals and postmortem human studies of smokers demonstrated β2-nAChR upregulation throughout the striatum, frontal cortex, anterior cingulate cortex, temporal cortex, occipital cortex, and cerebellum [73], suggesting greater levels of β2-nAChR desensitization a…”
BackgroundFasoli, F., Moretti, M., Zoli, M., Pistillo, F., Crespi, A., Clementi, F., McClure‐Begley, T. D., Marks, M. J., & Gotti, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.048 · Cited by 33 · see citing works
Cosgrove, K. P., Mitsis, E. M., Bois, F., Frohlich, E., Tamagnan, G. D., Krantzler, E., Perry, E., Maciejewski, P. K., Epperson, C. N., Allen, S., et al. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.042317 · Cited by 31 · see citing works
“High test–retest reliability and validity were recently reported for 123I-5-IA SPECT (22), and 123I-5-IA SPECT has demonstrated significantly higher b2-nAChR availability in recently abstinent tobacco smokers than in age- and sex-matched nonsmokers (23).”
BackgroundSelf-citationDecreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism
Dubroff, J. G., Doot, R. K., Falcone, M., Schnoll, R. A., Ray, R., Tyndale, R. F., Brody, A. L., Hou, C., Schmitz, A. M. T., & Lerman, C. E. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.155002 · Cited by 31 · see citing works
“SPECT molecular imaging studies of the nAChR a4b2* subtype have also shown that nAChR availability in smokers peaks after 1 wk of abstinence (22,24), suggesting the persistent occupation of nAChRs by nicotine.”
BackgroundLiu, W., & Li, M. D. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170801103009 · Cited by 27 · see citing works
“Long-term exposure to nicotine leads to an activity increase, amount upregulation, or both of nicotine binding sites in the brain of smokers [153, 154] and rodents subjected to repeated nicotine administration [155, 156].”
BackgroundYohn, N. L., Turner, J. R., & Blendy, J. A. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211706 · Cited by 28 · see citing works
“…Marks et al., 1992; Buisson and Bertrand, 2002) and has been confirmed in several systems including cultured cells and rodent and human tissues (Marks et al., 1983; Schwartz and Kellar, 1985; Benwell et al., 1988; Peng et al., 1994; Breese et al., 1997; Perry et al., 1999; Staley et al., 2006).”
BackgroundNeuroimaging, genetics and the treatment of nicotine addiction
Ray, R., Loughead, J., Wang, Z., Detre, J. A., Yang, E., Gur, R. C., & Lerman, C. E. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.05.021 · Cited by 29 · see citing works
Imaging Tobacco Smoking with PET and SPECT
Cosgrove, K., Esterlis, I., Sandiego, C. M., Petrulli, J. R., & Morris, E. D. (2015) · Current topics in behavioral neurosciences · doi:10.1007/978-3-319-13482-6_1 · Cited by 29 · see citing works
“At one week of abstinence, β2*-nAChR availability in the sensorimotor cortex was negatively correlated with the urge to smoke to relieve withdrawal symptoms (Staley et al. 2006).”
BackgroundMethodResultInfluentialSelf-citationArora, K., Alfulaij, N., Higa, J. K., Panee, J., & Nichols, R. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.453746 · Cited by 25 · see citing works
Arias, H. R., Targowska‐Duda, K. M., García‐Colunga, J., & Ortells, M. O. (2021) · Molecules · doi:10.3390/molecules26082149 · Cited by 30 · see citing works
“A common feature in both conditions is that of higher ACh concentrations compared to those in the normal population [20,30,31].”
Background
- Authors
- Staley, J. K., Krishnan-Sarin, S., Cosgrove, K. P., Krantzler, E., Frohlich, E., Perry, E., Dubin, J. A., Estok, K., Brenner, E., Baldwin, R. M., Tamagnan, G. D., Seibyl, J. P., Jatlow, P., Picciotto, M. R., London, E. D., O'Malley, S., & van Dyck, C. H.
- Affiliations
- Yale University (US)
- VA Connecticut Healthcare System (US)
- Institute for Neurodegenerative Disorders (US)
- University of California, Los Angeles (US)
- Corresponding author
- Staley, Julie K.
- ORCID
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2006-08-23
- Volume
- 26
- Issue
- 34
- Pages
- 8707-8714
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6674379
- OpenAlex
- W2165081822
- Semantic Scholar
- d596f30a7d3efb87530451c65cfcafb05ddb4f13
- Cited by
- 223
- References
- 64
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 4 · 2021: 4 · 2020: 26 · 2019: 5 · 2018: 16 · 2017: 8 · 2016: 13 · 2015: 11 · 2014: 17 · 2013: 20 · 2012: 9
- FWCI
- 5.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- nicotine withdrawal, smoking abstinence, nicotine dependence, striatum, cerebral cortex, urinary cotinine, carbon monoxide
- MeSH terms
- Adult, Animals, Azetidines, Cerebral Cortex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-08.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-08.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review